A Phase 1 interventional study of AX251 LAI 45 mg and AX251 LAI 90 mg in Schizophrenia, sponsored by Anxo Pharmaceutical Co., Ltd.. Recruiting at 4 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Anxo Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies in Schizophrenia with a site in India — 13 open to participants now, 14 under way, 2 of them phase 3. Schizophrenia · India.
Among the 78 studies in Schizophrenia with a site in India, this one is the 65th largest by planned enrollment of the 76 interventional ones that give a count, is one of 7 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 11 of the 13 other live ones, and was the 76th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →13 of the 78 studies in Schizophrenia with a site in India are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in India, United States, Australia and 8 more countries
Ages 5–17
Eli Lilly and Company · Sites in India, United States, Argentina and 4 more countries
Ages 18–55
Newron Pharmaceuticals SPA · Sites in India, United States, Argentina and 2 more countries
Ages 18+
Mapi Pharma Ltd. · Sites in India, Israel
Ages 18–64
All India Institute of Medical Sciences, Bhubaneswar · Sites in India
Ages 18–60
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 35 · Phase 4 10
First in 2003; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 201 across the 76 interventional studies, 333 across the 1 observational. Of the 63 that completed or were terminated, 32 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 78 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Anxo Pharmaceutical Co., Ltd. as lead sponsor.
Anxo Pharmaceutical Co., Ltd. has 1 study filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
4 of the studies in Schizophrenia with a site in India that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07184619Phase 3Newron Pharmaceuticals SPAEvenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia | 2027-03-31 |
| NCT07185815Mapi Pharma Ltd.Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine | 2026-12-31 |
| NCT07939347King's College LondonAVATAR Therapy for Distressing Voices in India and Ethiopia | 2027-09-30 |
| NCT07410507Eli Lilly and CompanyA Study of Brenipatide in Adult Participants With Schizophrenia | 2027-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 78 studies in Schizophrenia with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AX251 long-acting injectable (LAI) administered as a single dose in patients with schizophrenia. The study will include sequential dose-escalation cohorts to evaluate different dose levels of AX251 LAI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AX251 LAI 45mg
Drug: AX251 LAI 45 mg
AX251 LAI 90mg
Drug: AX251 LAI 90 mg
AX251 LAI 135mg
Drug: AX251 LAI 135 mg
AX251 LAI 180mg
Drug: AX251 LAI 180 mg
Cariprazine 45 mg
Cariprazine 90 mg
Cariprazine 135 mg
Cariprazine 180 mg
Pharmacokinetic Parameter
Maximum observed serum concentration of cariprazine and its metabolites desmethyl-cariprazine (DCAR) and didesmethyl-cariprazine (DDCAR) following a single dose of AX251 long-acting injectable (LAI).
Time frame: Day 1 pre-dose and 1, 2, 3, 4, 8, 12, and 24 hours post-dose. Days 3, 5, 7, 14, 21, 28, 42, 56, and 70
Safety: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number and proportion of participants experiencing treatment-emergent adverse events and serious adverse events during the study.
Time frame: Baseline to Day 70
Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 22 months after the start.
Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 22 months is above that.
Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.